Sydney, Australia 26 August 2024
Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce Board and senior team changes as Clarity progresses its multiple clinical and pre-clinical programs and navigates through this most exciting period in the Company’s history.
In line with the announcement dated 16 January 2024, Clarity’s Non-Executive Director, Mr Rob Thomas, has retired from the Board following the completion of his tenure on 23 August 2024. Non-Executive Director, Dr Chris Roberts, has been appointed Chair of the Audit and Risk Committee and will join the Nomination and Remuneration Committee. Thomas Ramdahl will join the Audit and Risk Committee, and fellow Non-Executive Director, Ms Rosanne Robinson, will take the role of Lead Independent Director.
Ms Michelle Parker, a long-time member of Clarity’s senior executive team, has been invited to the Board as an Executive Director and will officially join the Board upon completion of all formal requirements. Ms Parker was recently promoted to Chief Clinical Officer, having served in the roles of EVP, Global Clinical Operations and Head of Clinical Operations at Clarity for more than six years. Ms Parker has over 20 years of experience spanning nuclear medicine, positron emission tomography and pharmaceuticals in Australia and internationally. At Clarity, she has led the company’s rapidly advancing clinical strategy and program with 7 ongoing clinical trials. Prior to joining Clarity, Ms Parker held the position of Head of International Clinical Research Operations at Novartis Australia, a global pharmaceutical company, where she led a multi-disciplinary, high performing team of over 35 associates responsible for end-to-end clinical trial execution.
Other changes to the senior executive team include the internal appointment of Dr Othon Gervasio to Chief Medical Officer and Dr Matt Harris to Chief Scientific Officer. Ms Eva Lengyelova, VP of Clinical Development, joins the senior executive team.
Clarity has grown from 41 team members in July 2023 to 57 team members today, with approximately 60% located in Australia and 40% in the US. Since 1 July 2024, there has been a total of 13 promotions within the Company, which is approximately a quarter of the Clarity team, reflecting a strong culture of support and development, nurturing talent within the organisation. With this rapid growth, Clarity continues to have an organisation made up of approximately 70% female team members and very low turnover.
Clarity’s Executive Chairperson, Dr Alan Taylor, commented, “Having joined Clarity approximately eleven years ago when it was a shell company with no employees, I am extremely proud of the culture and team we have built together from the ground up, with a dedication towards having a flat structure, being a true meritocracy, and freeing ourselves from biases. We continue to build a strong team of people from a diverse range of backgrounds that has grown Clarity from the start-up idea it was just a decade ago, to today being the largest capitalised pharmaceutical biotechnology company listed on the Australian Securities Exchange that has been built solely with technology derived from the benchtop of Australian research. The success we have achieved to date is grounded by our team’s strong sense of purpose, dedication and focus on our shared goal of better treating children and adults with cancer.
“We look forward to welcoming Michelle to the Clarity Board. As a senior leader in our team for over six years, she has been a vital part of Clarity’s DNA and instrumental in advancing Clarity’s three key products from preclinical and early-stage clinical studies to late-stage and registrational Phase III trials. This has been pivotal in generating exceptional data, earning the status of best-in-class radiopharmaceuticals and attracting increasing attention from key opinion leaders and industry. Her insights and extensive experience will be highly valuable at the Board level during this crucial time for our Company, as we continue to advance the development of our pipeline of highly targeted theranostic radiopharmaceuticals.
“We also welcome our fellow team members who have joined us recently and thank those who continue to build the Clarity story with us. At Clarity, we have long instilled the emphasis on “ownership” within our team, and our broad-based employee share option plan firmly aligns our team towards the overall success of our Company. And although markets have been tumultuous since our listing, our team, a large majority of our shareholders and our Board have remained resolute as we look to build one of Australia’s most successful life sciences companies. As we focus our attention on this important goal, we are also cognisant of the fact that we are developing a large talent pool of exceptional experience that can further enhance the translation of science for many years to come.
“We lastly want to thank Rob Thomas for his assistance at the Board level since we listed on the ASX three years ago. Rob has been a great contributor to Clarity over that time, and we wish him every success.”
About Clarity Pharmaceuticals
Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing targeted copper theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.
Media Contacts
Clarity Pharmaceuticals
Dr Alan Taylor
Executive Chairperson
+61 (0)413 871 165
ataylor@claritypharm.com
Sodali & Co.
Catherine Strong
Investor/Media Relations
+61 (0)406 759 268
catherine.strong@sodali.com
This announcement has been authorised for release by the Executive Chairperson.
